Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the cloudy skies looming over the Pharmalot campus. After all, the birds are chirping and a mild breeze is wafting by. Moreover, this marks the middle of the week, which means we have managed to survive this far. And this calls for celebration, yes? So please join us as we quaff another cup of delicious stimulation. Remember, no prescription is required. Meanwhile, here are a few items of interest. Have a grand day, and drop us a line if you hear something saucy. …
The European Union will issue emergency legislation that will give it broad powers to curb exports for the next six weeks of Covid-19 vaccines manufactured in the bloc, a sharp escalation in its response to supply shortages at home that have created a political maelstrom amid a rising third wave on the continent, The New York Times reports. The new rules will make it harder for pharmaceutical companies producing Covid-19 vaccines in the European Union to export them and are likely to disrupt supply to Britain.
Johnson & Johnson (JNJ) is under pressure to deliver its promised 20 million Covid-19 vaccine doses by next week, as several state public health officials indicate they are receiving few or no shots this week and have no idea how much they will receive later, Roll Call tells us. The supply situation has frustrated Biden administration officials, who were counting on the single-dose J&J shot to reach underserved populations and accelerate a return to normal.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect